503 Stock Overview
Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People’s Republic of China and Hong Kong.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Lansen Pharmaceutical Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.79 |
| 52 Week High | HK$1.82 |
| 52 Week Low | HK$1.20 |
| Beta | 0.92 |
| 11 Month Change | 3.47% |
| 3 Month Change | 5.92% |
| 1 Year Change | 23.58% |
| 33 Year Change | 5.92% |
| 5 Year Change | 101.48% |
| Change since IPO | -59.35% |
Recent News & Updates
Recent updates
Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?
Sep 18
Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?
Mar 27Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet
Sep 27Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Dec 06Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
Sep 04We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings
Dec 28
Shareholder Returns
| 503 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0% | 5.3% | -0.2% |
| 1Y | 23.6% | 6.5% | -3.2% |
Return vs Industry: 503 exceeded the Hong Kong Pharmaceuticals industry which returned -10.6% over the past year.
Return vs Market: 503 exceeded the Hong Kong Market which returned -11.4% over the past year.
Price Volatility
| 503 volatility | |
|---|---|
| 503 Average Weekly Movement | 16.3% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.5% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 503's share price has been volatile over the past 3 months.
Volatility Over Time: 503's weekly volatility has increased from 10% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 652 | Li Chen | www.lansen.com.cn |
Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People’s Republic of China and Hong Kong. The company operates through Pharmaceuticals, Cosmetics Products, and Healthcare Products segments. It offers Chinese medicine; generic drugs; cosmetic products; and healthcare products.
Lansen Pharmaceutical Holdings Limited Fundamentals Summary
| 503 fundamental statistics | |
|---|---|
| Market cap | HK$750.60m |
| Earnings (TTM) | HK$57.82m |
| Revenue (TTM) | HK$506.62m |
13.0x
P/E Ratio1.5x
P/S RatioIs 503 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 503 income statement (TTM) | |
|---|---|
| Revenue | US$64.95m |
| Cost of Revenue | US$22.05m |
| Gross Profit | US$42.90m |
| Other Expenses | US$35.49m |
| Earnings | US$7.41m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.018 |
| Gross Margin | 66.05% |
| Net Profit Margin | 11.41% |
| Debt/Equity Ratio | 14.2% |
How did 503 perform over the long term?
See historical performance and comparison